Ranbaxy Plant Bans To Plague Daiichi Sankyo Long-Term
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo faces a long-term drain on production capacity for its generic drugs intended for the U.S. market despite a planned shift of manufacturing to the company’s costlier New Jersey plant.